The global ultrasound devices market is poised for robust growth from 2025 to 2035, driven by the rapid rise of portable and handheld systems, AI-enhanced imaging, and expanding applications in cardiology, radiology, and obstetrics. With a projected CAGR of 5.8–7.3%, the market is expected to surpass $16–18 billion by 2032, led by innovations in 3D/4D and Doppler technologies. North America continues to dominate revenue share, while Asia-Pacific emerges as the fastest-growing region due to increasing healthcare infrastructure and point-of-care demand. Key players like GE HealthCare, Philips, and Siemens are accelerating competition through AI integration and strategic acquisitions, signaling a transformative decade for accessible, non-invasive diagnostics worldwide.
The Global Biosimilars Market: Growth Drivers, Dominant Classes, and a High-Teen CAGR Outlook
The global biosimilars market is expanding rapidly due to the need for cost-effective biologic alternatives, projecting growth to over USD 150 billion by the mid-2030s with a high-teen CAGR. Monoclonal Antibodies (mAbs) are the dominant drug class (44.98% revenue share), while North America leads in current revenue, and the Asia Pacific region is the fastest-growing market. Growth is driven by patent expirations, rising chronic disease prevalence (oncology/autoimmune), and favorable regulatory environments, despite challenges related to patient perception and interchangeability.